Plasmapheresis
Blood Group Incompatibility
An antigenic mismatch between donor and recipient blood. Antibodies present in the recipient's serum may be directed against antigens in the donor product. Such a mismatch may result in a transfusion reaction in which, for example, donor blood is hemolyzed. (From Saunders Dictionary & Encyclopedia of Laboratory Medicine and Technology, 1984).
Plasma Exchange
Immunoglobulins, Intravenous
Immunoglobulin preparations used in intravenous infusion, containing primarily IMMUNOGLOBULIN G. They are used to treat a variety of diseases associated with decreased or abnormal immunoglobulin levels including pediatric AIDS; primary HYPERGAMMAGLOBULINEMIA; SCID; CYTOMEGALOVIRUS infections in transplant recipients, LYMPHOCYTIC LEUKEMIA, CHRONIC; Kawasaki syndrome, infection in neonates, and IDIOPATHIC THROMBOCYTOPENIC PURPURA.
Mushroom Poisoning
Purpura, Thrombotic Thrombocytopenic
An acquired, congenital, or familial disorder caused by PLATELET AGGREGATION with THROMBOSIS in terminal arterioles and capillaries. Clinical features include THROMBOCYTOPENIA; HEMOLYTIC ANEMIA; AZOTEMIA; FEVER; and thrombotic microangiopathy. The classical form also includes neurological symptoms and end-organ damage, such as RENAL FAILURE.
Myasthenia Gravis
A disorder of neuromuscular transmission characterized by weakness of cranial and skeletal muscles. Autoantibodies directed against acetylcholine receptors damage the motor endplate portion of the NEUROMUSCULAR JUNCTION, impairing the transmission of impulses to skeletal muscles. Clinical manifestations may include diplopia, ptosis, and weakness of facial, bulbar, respiratory, and proximal limb muscles. The disease may remain limited to the ocular muscles. THYMOMA is commonly associated with this condition. (Adams et al., Principles of Neurology, 6th ed, p1459)
Cryoglobulins
Isoantibodies
Guillain-Barre Syndrome
An acute inflammatory autoimmune neuritis caused by T cell- mediated cellular immune response directed towards peripheral myelin. Demyelination occurs in peripheral nerves and nerve roots. The process is often preceded by a viral or bacterial infection, surgery, immunization, lymphoma, or exposure to toxins. Common clinical manifestations include progressive weakness, loss of sensation, and loss of deep tendon reflexes. Weakness of respiratory muscles and autonomic dysfunction may occur. (From Adams et al., Principles of Neurology, 6th ed, pp1312-1314)
ABO Blood-Group System
The major human blood type system which depends on the presence or absence of two antigens A and B. Type O occurs when neither A nor B is present and AB when both are present. A and B are genetic factors that determine the presence of enzymes for the synthesis of certain glycoproteins mainly in the red cell membrane.
Ex vivo evaluation of a Taylor-Couette flow, immobilized heparinase I device for clinical application. (1/414)
Efficient and safe heparin anticoagulation has remained a problem for continuous renal replacement therapies and intermittent hemodialysis for patients with acute renal failure. To make heparin therapy safer for the patient with acute renal failure at high risk of bleeding, we have proposed regional heparinization of the circuit via an immobilized heparinase I filter. This study tested a device based on Taylor-Couette flow and simultaneous separation/reaction for efficacy and safety of heparin removal in a sheep model. Heparinase I was immobilized onto agarose beads via cyanogen bromide activation. The device, referred to as a vortex flow plasmapheretic reactor, consisted of two concentric cylinders, a priming volume of 45 ml, a microporous membrane for plasma separation, and an outer compartment where the immobilized heparinase I was fluidized separately from the blood cells. Manual white cell and platelet counts, hematocrit, total protein, and fibrinogen assays were performed. Heparin levels were indirectly measured via whole-blood recalcification times (WBRTs). The vortex flow plasmapheretic reactor maintained significantly higher heparin levels in the extracorporeal circuit than in the sheep (device inlet WBRTs were 1. 5 times the device outlet WBRTs) with no hemolysis. The reactor treatment did not effect any physiologically significant changes in complete blood cell counts, platelets, and protein levels for up to 2 hr of operation. Furthermore, gross necropsy and histopathology did not show any significant abnormalities in the kidney, liver, heart, brain, and spleen. (+info)"The FSGS factor:" enrichment and in vivo effect of activity from focal segmental glomerulosclerosis plasma. (2/414)
A circulating causative factor has been postulated in focal segmental glomerulosclerosis (FSGS). It has been shown that serum or plasma from some FSGS increases glomerular albumin permeability (Palb) in vitro. Palb greater than 0.5 (i.e., FS activity) is associated with recurrence after transplantation. Specimens from 15 FSGS patients were studied to document the presence of a permeability factor, to isolate this factor, to characterize its biochemical properties, and to show its effect in vivo. Total lipids were extracted by chloroform/methanol (2: 1); FS activity was absent from total lipid extract. Chylomicrons and lipoproteins were removed from the plasma with dextran sulfate, followed by sequential precipitation of proteins at 50 and 70% ammonium sulfate saturation. FS activity was retained in the 70% ammonium sulfate supernatant and exhibited a 100-fold purification. FS activity was lost after heating at 100 degrees C for 10 min or after protease digestion. Under nondenaturing conditions, electrophoresis of the FSGS 70% supernatant showed a prominent low molecular weight band that was not evident in the 70% supernatant from normal plasma. Dialysis and centrifugation-based membrane ultrafiltration of the FSGS factor indicated a molecular size between 30 and 50 kD. Injection of the 70% FSGS supernatant into rats caused a threefold increase in urine protein in collections from 6 to 24 h after injection. No increase in proteinuria occurred in rats injected with 70% supernatant from normal individuals. It is concluded that the FSGS factor is a low molecular weight protein with the potential to increase Palb in vitro and to cause proteinuria in vivo. (+info)The natural course of hepatitis C virus infection 18 years after an epidemic outbreak of non-A, non-B hepatitis in a plasmapheresis centre. (3/414)
BACKGROUND: The natural history of hepatitis C virus (HCV) infection is variable and factors determining the course of the illness are unclear. AIMS: To determine the natural course of HCV infection in a well characterised group of patients 18 years after an epidemic outbreak of non-A, non-B hepatitis at a plasmapheresis centre. METHODS: Between 1994 and 1996, 20 of 30 affected individuals were studied. HCV infection was confirmed using second and third generation ELISA test kits. HCV RNA was detected by a polymerase chain reaction (PCR) method and HCV genotyping was performed by analysing amplicons from the conserved 5'-non-translated region generated by nested PCR. Thirty two liver biopsies were carried out in 14 patients. RESULTS: HCV antibodies were detected in all subjects. Eighteen patients had abnormal liver enzymes and 17 were HCV RNA positive, all of whom were infected with genotype 1a. Ninety per cent of this cohort showed evidence of chronic HCV infection with 50% having progressive liver disease and 20% cirrhosis 18 years after acute onset of non-A, non-B hepatitis. Considerable variation in disease outcome occurred between individuals and no correlation with clinical features of the acute illness was found. CONCLUSIONS: Variability in the consequences of HCV infection in cases infected with the same virus suggests that host factors are important in determining disease outcome. The factors which determine differences in the natural history of the disease still remain to be elucidated. (+info)Pathogenesis and treatment of HTLV-I associated myelopathy. (4/414)
That HTLV-I is not a latent infection is indicated by the detection of mRNA in the peripheral blood and CNS of patients with HTLV-I infection and by the persisting humoral and cellular immune responses. Indeed the frequency of anti-HTLV CTL is extremely high. The reduction in anti-TAX CTL frequency following reduction in proviral load suggests that removal of viral antigen may result in a reduced inflammatory response at least in peripheral blood and although the clinical data should be interpreted with caution, perhaps in the CNS. Patients with more advanced disease, and possibly fixed deficits may not benefit from either anti-inflammatory or antiretroviral treatment. The patients with most to gain are those with least deficit in whom early diagnosis and treatment will depend on raising awareness of HTLV-I beyond the neurological community. Many patients with HAM first present to a urologist or gynaecologist with bladder dysfunction or may have been seen in the genitourinary clinical with impotence or positive treponemal serology, which in the older patient is often the result of childhood infection with Treponema pallidum pertenue. Investigation of these patients should include HTLV-I serology and further investigation of HTLV-I positive patients should include proviral load measurements as well as markers of inflammation. Treatments whether antiviral or anti-inflammatory should be assessed for their effect on both as well as a clinical response. (+info)Acquired factor VIII inhibitor in a non-hemophilic patient with chronic hepatitis C viral infection. (5/414)
Production of coagulation factor VIII inhibitor is rarely encountered in non-hemophilic patients. A 63-year-old Japanese male suffered from severe bleeding tendency caused by this inhibitor. Although he did not have malignancy or collagen disease, he had chronic hepatitis C virus (HCV) infection. Although HCV is known to induce production of various autoimmune antibodies, this may be the first report of a case with both acquired factor VIII inhibitor and HCV infection. (+info)Calcinosis cutis and intestinal pseudoobstruction in a patient with adult onset Still's disease associated with recurrent relapses of disordered coagulopathy. (6/414)
Adult onset Still's disease (AOSD) is a systemic inflammatory disorder of unknown origin, characterized by a typical spiking fever, evanescent salmon-colored rash, polyarthralgia, and myalgia. Calcinosis cutis and gastrointestinal involvement have rarely been noted in AOSD. We herein describe a 54-year-old woman who demonstrated repeated disseminated intravascular coagulation (DIC), and adult respiratory distress syndrome (ARDS), associated with AOSD. The patient also revealed a remarkable degree of digital calcinosis cutis and intestinal pseudoobstruction. A connective tissue disease, such as systemic sclerosis, might have been the underlying factor in the latter two symptoms. (+info)Systemic lupus erythematosus demonstrating serum anti-GM1 antibody, with sudden onset of drop foot as the initial presentation. (7/414)
In systemic lupus erythematosus (SLE), peripheral neuropathies are relatively uncommon and rarely present as the initial symptom. We herein describe a 61-year-old woman who developed a sudden onset of drop foot, which was indistinguishable from Guillain-Barre syndrome based on the clinical symptoms alone. Antibodies against ganglioside GM1 were detected in the serum, while no antibodies to Campylobacter jejuni were observed. An electrophysiological study showed axonal impairment rather than demyelination. A pathological examination of a sural nerve biopsy specimen and further laboratory examinations suggested the observed peripheral neuropathies to have arisen due to lupus vasculitis. The serological activities of SLE responded well to treatment with corticosteroids, mizoribine and immunoadsorption therapies, however, the drop foot symptoms did not change remarkably. (+info)Role of plasmalogens in the enhanced resistance of LDL to copper-induced oxidation after LDL apheresis. (8/414)
Extracorporeal reduction of plasma low density lipoproteins (LDLs) by LDL apheresis was shown to attenuate the proatherogenic influences of LDL, such as impairment of vasodilation and increased monocyte adhesion to the endothelium. In 16 patients with familial hypercholesterolemia, we analyzed whether LDL apheresis by the heparin precipitation procedure affected the oxidative resistance of LDL. Plasma LDL cholesterol concentrations were reduced by 65% after the apheresis. The lag time of copper-mediated LDL oxidation was increased from 103 to 117 minutes (P<0.0005). The LDL contents of alpha-tocopherol and beta-carotene, as well as the ratio of monounsaturated to polyunsaturated fatty acids in LDL, were not altered. However, the LDL apheresis induced a 15% increase in the LDL contents of plasmalogen phospholipids (P<0.0005), a class of ether phospholipids that were recently shown to prevent lipid oxidation. The phosphatidylcholine (PC) to lysoPC ratio was elevated by 16% after the apheresis (P<0.0005). The percent increase in LDL plasmalogen phospholipids showed a close association with the increased lag time after apheresis (P<0.0005). The LDL plasmalogen contents of the blood samples from patients and from normolipidemic donors were also positively related to the lag time (P<0.005). In vitro loading of LDL with plasmalogen phospholipids resulted in a prolongation of the lag time and an increase in the PC/lysoPC ratio. In conclusion, the rapid rise in LDL contents of plasmalogen phospholipids most probably causes the increase in lag time after LDL apheresis. Plasmalogens appear to play an important role in the oxidation resistance of LDL in vivo. (+info)Plasmapheresis is a medical procedure that involves the separation and extraction of plasma from blood, followed by the return of the remaining components or replacement fluids to the donor or patient, which is used for therapeutic purposes such as removing harmful antibodies, toxins, or excessive immune complexes from the circulation.
Plasmapheresis is a medical procedure where the liquid portion of the blood (plasma) is separated from the blood cells. The plasma, which may contain harmful substances such as antibodies or toxins, is then removed and replaced with fresh plasma or a plasma substitute. The remaining blood cells are mixed with the new plasma and returned to the body. This process is also known as therapeutic plasma exchange (TPE). It's used to treat various medical conditions including certain autoimmune diseases, poisonings, and neurological disorders.
Blood group incompatibility refers to the condition that arises when there is an antigenic mismatch between donor and recipient blood types, leading to the destruction of transfused red blood cells by the recipient's immune system.
Blood group incompatibility refers to a situation where the blood type of a donor and a recipient are not compatible, leading to an immune response and destruction of the donated red blood cells. This is because the recipient's immune system recognizes the donor's red blood cells as foreign due to the presence of incompatible antigens on their surface.
The most common type of blood group incompatibility occurs between individuals with different ABO blood types, such as when a person with type O blood receives type A, B, or AB blood. This can lead to agglutination and hemolysis of the donated red blood cells, causing potentially life-threatening complications such as hemolytic transfusion reaction.
Another type of blood group incompatibility occurs between Rh-negative mothers and their Rh-positive fetuses. If a mother's immune system is exposed to her fetus's Rh-positive red blood cells during pregnancy or childbirth, she may develop antibodies against them. This can lead to hemolytic disease of the newborn if the mother becomes pregnant with another Rh-positive fetus in the future.
To prevent these complications, it is essential to ensure that donated blood is compatible with the recipient's blood type before transfusion and that appropriate measures are taken during pregnancy and childbirth to prevent sensitization of Rh-negative mothers to Rh-positive red blood cells.
'Plasma exchange' is a medical procedure that involves the extracorporeal separation and removal of a patient's plasma, followed by its replacement with fresh frozen plasma, albumin or a synthetic colloid, to remove harmful antibodies, toxins, or excessive substances from the bloodstream.
Plasma exchange, also known as plasmapheresis, is a medical procedure where the liquid portion of the blood (plasma) is separated from the blood cells. The plasma, which may contain harmful substances such as antibodies, clotting factors, or toxins, is then removed and replaced with fresh plasma or a plasma substitute. This process helps to remove the harmful substances from the blood and allows the body to replenish its own plasma with normal components. Plasma exchange is used in the treatment of various medical conditions including autoimmune diseases, poisonings, and certain types of kidney diseases.
Intravenous Immunoglobulins (IVIG) are a sterile preparation of pooled human immunoglobulins containing antibodies against various infectious agents and their toxins, administered intravenously to provide passive immunity in patients with immune deficiencies, certain inflammatory diseases, or following exposure to pathogens.
Intravenous Immunoglobulins (IVIG) are a preparation of antibodies, specifically immunoglobulins, that are derived from the plasma of healthy donors. They are administered intravenously to provide passive immunity and help boost the immune system's response in individuals with weakened or compromised immune systems. IVIG can be used for various medical conditions such as primary immunodeficiency disorders, secondary immunodeficiencies, autoimmune diseases, and some infectious diseases. The administration of IVIG can help prevent infections, reduce the severity and frequency of infections, and manage the symptoms of certain autoimmune disorders. It is important to note that while IVIG provides temporary immunity, it does not replace a person's own immune system.
'Mushroom poisoning' is a form of food poisoning caused by the ingestion of toxic substances present in certain species of mushrooms, which can lead to a wide range of symptoms, from gastrointestinal distress to potentially life-threatening organ damage or failure.
Mushroom poisoning refers to the adverse health effects that occur after ingesting toxic mushrooms. These effects can range from mild gastrointestinal symptoms like nausea, vomiting, and diarrhea, to severe neurological and systemic reactions, including hallucinations, organ failure, and even death in serious cases. The severity of the poisoning depends on several factors, including the type and amount of toxic mushroom consumed, the age and health status of the individual, and the time elapsed between ingestion and medical treatment. It is crucial to seek immediate medical attention if mushroom poisoning is suspected, as some symptoms may not appear until several hours or days after consumption, and delays in treatment can lead to more severe outcomes.
Thrombotic purpura is a rare blood disorder characterized by the formation of small blood clots throughout the body, leading to low platelet count, hemolytic anemia, neurological symptoms, and kidney failure.
Thrombotic thrombocytopenic purpura (TTP) is a rare but serious blood disorder. It's characterized by the formation of small blood clots throughout the body, which can lead to serious complications such as low platelet count (thrombocytopenia), hemolytic anemia, neurological symptoms, and kidney damage.
The term "purpura" refers to the purple-colored spots on the skin that result from bleeding under the skin. In TTP, these spots are caused by the rupture of red blood cells that have been damaged by the abnormal clotting process.
TTP is often caused by a deficiency or inhibitor of ADAMTS13, a protein in the blood that helps to regulate the formation of blood clots. This deficiency or inhibitor can lead to the formation of large clots called microthrombi, which can block small blood vessels throughout the body and cause tissue damage.
TTP is a medical emergency that requires prompt treatment with plasma exchange therapy, which involves removing and replacing the patient's plasma to restore normal levels of ADAMTS13 and prevent further clotting. Other treatments may include corticosteroids, immunosuppressive drugs, and rituximab.
Myasthenia Gravis is an autoimmune neuromuscular disorder characterized by varying degrees of weakness in the skeletal muscles, particularly those controlling eye and eyelid movement, facial expression, chewing, talking, and swallowing.
Myasthenia Gravis is a long-term autoimmune neuromuscular disorder that leads to muscle weakness. It occurs when communication between nerves and muscles is disrupted at the nerve endings, resulting in fewer impulses being transmitted to activate the muscles. This results in muscle weakness and rapid fatigue. The condition can affect any voluntary muscle, but it most commonly affects muscles of the eyes, face, throat, and limbs. Symptoms may include drooping eyelids (ptosis), double vision (diplopia), difficulty swallowing, slurred speech, and weakness in the arms and legs. The severity of symptoms can vary greatly from person to person, ranging from mild to life-threatening.
The disorder is caused by an abnormal immune system response that produces antibodies against the acetylcholine receptors in the postsynaptic membrane of the neuromuscular junction. These antibodies block or destroy the receptors, which leads to a decrease in the number of available receptors for nerve impulses to activate the muscle fibers.
Myasthenia Gravis can be treated with medications that improve communication between nerves and muscles, such as cholinesterase inhibitors, immunosuppressants, and plasmapheresis or intravenous immunoglobulin (IVIG) to remove the harmful antibodies from the blood. With proper treatment, many people with Myasthenia Gravis can lead normal or nearly normal lives.
Cryoglobulins are immunoglobulins that precipitate at reduced temperatures, such as below 37°C, and dissolve upon rewarming, which can be found in various pathological conditions like infections, autoimmune diseases, and lymphoproliferative disorders.
Cryoglobulins are immunoglobulins (a type of antibody) that precipitate or become insoluble at reduced temperatures, typically below 37°C (98.6°F), and re-dissolve when rewarmed. They can be found in various clinical conditions such as infections, inflammatory diseases, and lymphoproliferative disorders.
The presence of cryoglobulins in the blood can lead to a variety of symptoms, including purpura (a type of skin rash), arthralgias (joint pain), neuropathy (nerve damage), and glomerulonephritis (kidney inflammation). The diagnosis of cryoglobulinemia is made by detecting the presence of cryoglobulins in the serum, which requires special handling and processing of the blood sample. Treatment of cryoglobulinemia depends on the underlying cause and may include medications such as corticosteroids, immunosuppressive agents, or targeted therapies.
Isoantibodies are antibodies produced by the immune system in response to encountering foreign antigens, typically from different individuals of the same species, such as during blood transfusions or pregnancy, where they play a crucial role in transfusion reactions and hemolytic disease of the newborn.
Isoantibodies are antibodies produced by the immune system that recognize and react to antigens (markers) found on the cells or tissues of another individual of the same species. These antigens are typically proteins or carbohydrates present on the surface of red blood cells, but they can also be found on other cell types.
Isoantibodies are formed when an individual is exposed to foreign antigens, usually through blood transfusions, pregnancy, or tissue transplantation. The exposure triggers the immune system to produce specific antibodies against these antigens, which can cause a harmful immune response if the individual receives another transfusion or transplant from the same donor in the future.
There are two main types of isoantibodies:
1. Agglutinins: These are IgM antibodies that cause red blood cells to clump together (agglutinate) when mixed with the corresponding antigen. They develop rapidly after exposure and can cause immediate transfusion reactions or hemolytic disease of the newborn in pregnant women.
2. Hemolysins: These are IgG antibodies that destroy red blood cells by causing their membranes to become more permeable, leading to lysis (bursting) of the cells and release of hemoglobin into the plasma. They take longer to develop but can cause delayed transfusion reactions or hemolytic disease of the newborn in pregnant women.
Isoantibodies are detected through blood tests, such as the crossmatch test, which determines compatibility between a donor's and recipient's blood before transfusions or transplants.
Guillain-Barré syndrome is an acute autoimmune inflammatory disorder of the peripheral nervous system, often precipitated by an infectious agent, characterized by rapid onset of ascending paralysis, areflexia, and occasionally autonomic dysfunction.
Guillain-Barré syndrome (GBS) is a rare autoimmune disorder in which the body's immune system mistakenly attacks the peripheral nervous system, leading to muscle weakness, tingling sensations, and sometimes paralysis. The peripheral nervous system includes the nerves that control our movements and transmit signals from our skin, muscles, and joints to our brain.
The onset of GBS usually occurs after a viral or bacterial infection, such as respiratory or gastrointestinal infections, or following surgery, vaccinations, or other immune system triggers. The exact cause of the immune response that leads to GBS is not fully understood.
GBS typically progresses rapidly over days or weeks, with symptoms reaching their peak within 2-4 weeks after onset. Most people with GBS experience muscle weakness that starts in the lower limbs and spreads upward to the upper body, arms, and face. In severe cases, the diaphragm and chest muscles may become weakened, leading to difficulty breathing and requiring mechanical ventilation.
The diagnosis of GBS is based on clinical symptoms, nerve conduction studies, and sometimes cerebrospinal fluid analysis. Treatment typically involves supportive care, such as pain management, physical therapy, and respiratory support if necessary. In addition, plasma exchange (plasmapheresis) or intravenous immunoglobulin (IVIG) may be used to reduce the severity of symptoms and speed up recovery.
While most people with GBS recover completely or with minimal residual symptoms, some may experience long-term disability or require ongoing medical care. The prognosis for GBS varies depending on the severity of the illness and the individual's age and overall health.
The ABO blood-group system is a genetic classification system based on the presence or absence of antigens A and B on red blood cells, and antibodies against them in plasma, which plays a crucial role in blood transfusion compatibility and organ transplantation.
The ABO blood-group system is a classification system used in blood transfusion medicine to determine the compatibility of donated blood with a recipient's blood. It is based on the presence or absence of two antigens, A and B, on the surface of red blood cells (RBCs), as well as the corresponding antibodies present in the plasma.
There are four main blood types in the ABO system:
1. Type A: These individuals have A antigens on their RBCs and anti-B antibodies in their plasma.
2. Type B: They have B antigens on their RBCs and anti-A antibodies in their plasma.
3. Type AB: They have both A and B antigens on their RBCs but no natural antibodies against either A or B antigens.
4. Type O: They do not have any A or B antigens on their RBCs, but they have both anti-A and anti-B antibodies in their plasma.
Transfusing blood from a donor with incompatible ABO antigens can lead to an immune response, causing the destruction of donated RBCs and potentially life-threatening complications such as acute hemolytic transfusion reaction. Therefore, it is crucial to match the ABO blood type between donors and recipients before performing a blood transfusion.
Plasmapheresis
Almost all plasmapheresis in the US is performed by automated methods. In some cases, automated plasmapheresis is used to ... Plasmapheresis of the autologous and exchange types is used to treat a variety of disorders, including those of the immune ... During plasmapheresis, blood, which consists of blood cells and a clear liquid called blood plasma, is initially taken out of ... The modern plasmapheresis process itself originated in the U.S. National Cancer Institute between 1963 and 1968, where ...
W. Ian Lipkin
While at UCL, he worked with John Newsom-Davis, who was utilizing plasmapheresis to better understand myasthenia gravis, a ... Hamblin, Terry (1998). "Plasmapheresis". Encyclopedia of Immunology. pp. 1969-1971. doi:10.1006/rwei.1999.0495. ISBN ... which he showed could be treated with plasmapheresis and demonstrated early life exposure to viral infections affects ...
Multiple sclerosis drug pipeline
Plasmapheresis. Pattern II MS lesions have been reported to respond to plasmapheresis, which points to something pathogenic ...
Pyoderma gangrenosum
... or plasmapheresis. Superficial granulomatous pyoderma Brown recluse spider bite Jackson JM, Callen JP (April 23, 2012). Elston ...
Multiple myeloma
Plasmapheresis, hemodialysis, and chemotherapy". Archives of Internal Medicine. 150 (4): 863-869. doi:10.1001/archinte. ... Paul M, Walker F, Bear RA (November 1982). "Plasmapheresis therapy in a patient with multiple myeloma". Canadian Medical ...
James O. McNamara
Andrews, P. I.; Dichter, M. A.; Berkovic, S. F.; Newton, M. R.; McNamara, J. O. (January 1996). "Plasmapheresis in Rasmussen's ...
Transverse myelitis
One treatment option includes plasmapheresis. Recovery from TM is variable between individuals and also depends on the ...
Pemphigus
Plasmapheresis may also be useful. Pemphigus foliaceus has been recognized in pet dogs, cats, and horses, and is the most ...
Antiserum
This procedure is called plasmapheresis. Mupapa, K; Massamba, M; Kibadi, K; Kuvula, K; Bwaka, A; Kipasa, M; Colebunders, R; ... plasmapheresis). For example, convalescent serum, passive antibody transfusion from a previous human survivor, used to be the ...
Leonard Rowntree
The next year the team described plasmapheresis. In 1918, he joined the US Army where he led studies of aviation medicine. That ... the intravenous pyelogram and plasmapheresis. Rowntree was awarded the Medal for Merit in 1946. Rowntree was born in London, ...
Mucous membrane pemphigoid
Plasmapheresis appears to help some cases. Sometimes surgical procedures are required to repair scars, prevent complications ...
Grifols
In the United States the company owns 230 plasmapheresis centres, where it collects around 5.8 million litres of plasma per ... Grífols-Lucas, JA (1952). "Use of plasmapheresis in blood donors". British Medical Journal. 1 (4763): 854. doi:10.1136/bmj. ... Grifols Lucas was the first researcher to publish the plasmapheresis procedure in 1952. The company introduced its liquid IVIG ...
Microangiopathic hemolytic anemia
Plasmapheresis is one treatment for TTP; corticosteroids should also be considered. {mcn} Lechner K, Obermeier HL (July 2012 ...
Pulmonary-renal syndrome
Plasmapheresis can be used in some circumstances.[citation needed] West, SC; Arulkumaran, N; Ind, PW; Pusey, CD (May 2013). " ...
Antiphospholipid syndrome
In refractory cases plasmapheresis may be used.[citation needed] The long-term prognosis for APS is determined mainly by ...
Serum sickness
Use of plasmapheresis has also been described. Serum sickness is becoming less common over time. Many drugs based on animal ...
Leukoreduction
Apheresis Plasmapheresis Venipuncture "Creutzfeldt-Jakob disease - Prevention". nhs.uk. 2017-10-23. Retrieved 2023-06-22. ...
Opsoclonus myoclonus syndrome
Trazodone can be useful against irritability and sleep problems Additional treatment options include plasmapheresis for severe ... recurrent opsoclonus-myoclonus syndrome responding to plasmapheresis". Pediatr. Neurol. 33 (5): 365-7. doi:10.1016/j. ...
Biopharma LLC
Plasma is collected from donors by hardware plasmapheresis. In September 2020 Biopharma has completed clinical trials of ...
Solar urticaria
In more extreme cases, plasmapheresis can be considered. This technique is used to remove the blood plasma or fluid in the red ... In more extreme cases, the use of immunosuppressive drugs and even plasmapheresis may be considered. The initial discovery of ...
Autoimmune retinopathy
Plasmapheresis involves separating blood into two parts - blood cells and plasma. The blood plasma components, such as the ... Often, this is treatment is combined with plasmapheresis. Instead of treating the plasma and blood cells, they are replaced ... Methods of treatment include intravenous immunoglobulin (IVIG), plasmapheresis, and corticosteroids. Immunoglobulin samples are ...
Anti-Hu associated encephalitis
Armstrong MB, Robertson PL, Castle VP (2005). "Delayed, recurrent opsoclonus-myoclonus syndrome responding to plasmapheresis". ...
Amanita phalloides
Jander S, Bischoff J, Woodcock BG (2000). "Plasmapheresis in the treatment of Amanita phalloides poisoning: II. A review and ... plasmapheresis, and peritoneal dialysis have occasionally yielded success, but overall do not appear to improve outcome. In ...
Neuromyelitis optica spectrum disorder
The most established method for antibody removal is plasmapheresis. A number of drugs are being studied: aquaporumab (non- ... Plasmapheresis can be an effective treatment when attacks progress after the administration of corticosteroids. This treatment ...
Amanita virosa
Jander S, Bischoff J, Woodcock BG (2000). "Plasmapheresis in the treatment of Amanita phalloides poisoning: II. A review and ... plasmapheresis, and peritoneal dialysis have occasionally yielded success but overall do not appear to improve outcome. In ...
Kaneka Corporation
In 1986, the company developed and marketed plasmapheresis system. In 1989, the company developed modified PET resin named " ...
MOG antibody disease
... neuromyelitis optica spectrum disorders treated with plasmapheresis]". No to Hattatsu = Brain and Development. 48 (3): 199-203 ...
Refsum disease
Plasmapheresis is another medical intervention used to treat patients. This involves the filtering of blood to ensure there is ...
Postvaccinal encephalitis
"Improvement of advanced postvaccinal demyelinating encephalitis due to plasmapheresis". Neuropsychiatric Disease and Treatment ...
Hermansky-Pudlak syndrome
However, sometimes plasmapheresis is needed in the perioperative period.[citation needed] Ophthalmologists should try to avoid ...
Plasmapheresis - Wikipedia
Almost all plasmapheresis in the US is performed by automated methods. In some cases, automated plasmapheresis is used to ... Plasmapheresis of the autologous and exchange types is used to treat a variety of disorders, including those of the immune ... During plasmapheresis, blood, which consists of blood cells and a clear liquid called blood plasma, is initially taken out of ... The modern plasmapheresis process itself originated in the U.S. National Cancer Institute between 1963 and 1968, where ...
Plasmapheresis, GM-CSF, and alveolar proteinosis
Plasmapheresis - Health Library
Plasmapheresis is a procedure to exchange plasma in the blood. Plasma is the liquid part of the blood. It does not have any ... Plasmapheresis takes out certain proteins from the plasma. These proteins mistakenly attack the bodys own healthy cells. This ... Plasmapheresis. (Plasma Exchange; Therapeutic Plasma Exchange). How to Say It: plaz-mah-fer-EE-sis ... Walters G. Role of therapeutic plasmapheresis in ANCA-associated vasculitis. Pediatr Nephrol. 2016;31(2):217-25. ...
Plasmapheresis machine - NexSys PCS® - HAEMONETICS
Plasmapheresis machine - All medical device manufacturers
Find your plasmapheresis machine easily amongst the 11 products from the leading brands (Haier Biomedical, Fenwal, HAEMONETICS ... Inspired by extensive customer input, the NexSys PCS® plasmapheresis system is designed to improve the key performance ... CPUs for failsafe operations CE certified Manufactured by NIKKISO MA-03 Multifunctional Direct Hemoperfusion Plasmapheresis ... and quality of plasmapheresis devices for the plasma collection industry. It utilizes advanced technological features, ... ...
Plasmapheresis in Raynaud's phenomenon in systemic sclerosis: a microcirculatory study. | Read by QxMD
Plasmapheresis in Raynauds phenomenon in systemic sclerosis: a microcirculatory study.. M J Jacobs, P J Jörning, E J Van Rhede ... After 4 plasmaphereses, once a week, all patients claimed explicit improvement of their complaints. Raynauds phenomenon and ... In these patients, plasmapheresis can be considered to treat severe ischemia of the digits. ... RBC aggregation and plasma viscosity were significantly lower (p less than 0.001) after the last plasmapheresis than before ...
Plasmapheresis
'plasmapheresis' | téarma...
Myasthenia Gravis and Pregnancy: Overview, Etiology, Impact in Pregnancy
Plasmapheresis and Intravenous Immunoglobulin Therapy. Plasmapheresis. Plasmapheresis is an expensive procedure used in ... Together with steroids, plasmapheresis is a very effective treatment. It consists of 3-6 exchanges of 2-3 L over 1-2 weeks. It ... Plasmapheresis can be used for disease control. In 1986, Ip et al used thymectomy as a treatment for myasthenic crisis during ... As the etiology of preterm delivery is unknown, plasmapheresis is (or may be) associated with preterm delivery. Other ...
Pages that link to "Plasmapheresis" - CCMDB Wiki
Plasmapheresis Treatment Center In Mexico | Oasis Medical
Approach to optic neuritis: An update : Indian Journal of Ophthalmology
What to Expect During Your First Plasmapheresis Treatment
Congratulations! As a medical process, Houston plasmapheresis separates ... You have been diagnosed with a condition that requires plasmapheresis treatment. ... What are the benefits of plasmapheresis?. Plasmapheresis treatment can be incredibly beneficial for people suffering from ... Congratulations! As a medical process, Houston plasmapheresis separates plasma from whole blood. At the time of plasma exchange ...
REVIEW ON USE OF PLASMAPHERESIS IN FOGOSELVAGEM | 51670
Goodpasture Syndrome Treatment & Management: Approach Considerations, Plasmapheresis, Immunosuppressive Therapy
Plasmapheresis. In published case series and one randomized trial, plasmapheresis has been shown to be beneficial in the ... The plasmapheresis is continued for 2-3 weeks or until the patients clinical course has improved and serum anti-GBM antibodies ... 83.5%), and the plasmapheresis group also experienced fewer plasma-associated side effects. Patient survival and renal survival ... Treatment consists of plasmapheresis and cyclophosphamide, but this appears to be limited. Retransplantation of patients with ...
EN
Plasmapheresis in Dogs - Conditions Treated, Procedure, Efficacy, Recovery, Cost, Considerations, Prevention
Dogs with these conditions can undergo plasmapheresis to remove and replace components of their plasma. ... Efficacy of Plasmapheresis in Dogs. Plasmapheresis is effective for rapid reduction of toxins or immune complexes in plasma in ... Plasmapheresis Recovery in Dogs. During and immediately after plasmapheresis therapy, your dog may experience a drop in blood ... Cost of Plasmapheresis in Dogs. Multiple plasmapheresis procedures may be required, which will contribute to variations in cost ...
Optimizing Lupus Treatment: Plasmapheresis and Pulse Cyclophosphamide in the LPSG Trial
The Lupus Plasmapheresis Study Group (LPSG) aims to study the potential benefits of plasmapheresis and pulse cyclophosphamide ... To find out how well plasmapheresis and pulse cyclophosphamide work together to treat severe SLE, the Lupus Plasmapheresis ... Optimizing Lupus Treatment: Plasmapheresis and Pulse Cyclophosphamide in the LPSG Trial. by James Robert ... The Lupus Plasmapheresis Study Group (LPSG): Collaborative Research for a Better Future. In order to learn more about the ...
William Alford - Plasmapheresis as a Therapy for Chronic Intestinal Pseudo-Obstruction
Plasmapheresis may have promise as a therapy for CIP and consideration seems warranted. References. Abell T, Duncan U, Kuns J, ... Plasmapheresis as a Therapy for Chronic Intestinal Pseudo-Obstruction. William Alford 1996 ... Plasmapheresis as a Therapy for Chronic Intestinal Pseudo-Obstruction. William Alford 1996 Chronic Intestinal Pseudo- ... In this case, plasmapheresis (PP) allows a recipient to accept just plasma the yellow liquid in which the blood cells are ...
Breaking the cycle of childhood obesity
Amiodarone-Induced Thyroid Storm Causing Sustained Monomorphic Ventricular Tachycardia Treated With Plasmapheresis: A...
Amiodarone-Induced Thyroid Storm Causing Sustained Monomorphic Ventricular Tachycardia Treated With Plasmapheresis: A ... Under the circumstances of limited medical therapies, plasmapheresis can be an effective treatment option.. J Med Cases. 2020; ... Amiodarone-Induced Thyroid Storm Causing Sustained Monomorphic Ventricular Tachycardia Treated With Plasmapheresis: A ... amiodarone-induced thyrotoxicosis and thyroid storm leading to refractory ventricular tachycardias treated with plasmapheresis ...
My IVIG PowerPort Problem Diagnosed - IVIG and Plasmapheresis - Lambert-Eaton News Forums
Transitioning from IVIG to Rituxan - IVIG and Plasmapheresis - Lambert-Eaton News Forums
Rinsing after spinning: plasmapheresis in EBV-related post-infectious cerebellitis - ePrints - Newcastle University
Plasmapheresis in the treatment of thrombotic thrombocytopenic purpura | Blood | American Society of Hematology
Two patients with thrombotic thrombocytopenic purpura (TTP) have recovered completely after intensive plasmapheresis. The ... Plasmapheresis in the treatment of thrombotic thrombocytopenic purpura RM Bukowski, RM Bukowski ... RM Bukowski, JW King, JS Hewlett; Plasmapheresis in the treatment of thrombotic thrombocytopenic purpura. Blood 1977; 50 (3): ... Plasmapheresis appears to be useful therapy for some patients with this syndrome. ...
Double‐Blind Evaluation of Plasmapheresis in Schizophrenic Patients: A Pilot Study<...
... blind evaluation of the effects of plasmapheresis on symptoms of schizophrenia. Also, plasmapheresis was felt to be an ... blind evaluation of the effects of plasmapheresis on symptoms of schizophrenia. Also, plasmapheresis was felt to be an ... blind evaluation of the effects of plasmapheresis on symptoms of schizophrenia. Also, plasmapheresis was felt to be an ... blind evaluation of the effects of plasmapheresis on symptoms of schizophrenia. Also, plasmapheresis was felt to be an ...
Plasmapheresis and Different Longevity Therapies to Change the Way forward for Wellness - Healthy Journaling
Whereas plasmapheresis has been round for a number of many years and has lengthy been utilized in treating autoimmune illnesses ... Plasmapheresis helps revert the affected persons plasma profile to that of a youthful particular person thereby offering ... "Scientists have proven that Plasmapheresis seems to have promising regenerative results in animals and people. It seems to be ... Peak Human is the primary and solely medical heart in Canada that gives to carry out plasmapheresis for mind well being and ...
The Prohibited List | World Anti Doping Agency
The status of plasmapheresis is different for plasma donors and recipients:. *For the plasma donor, plasmapheresis is ... For the plasma recipient, who is receiving plasma from a different donor, plasmapheresis is not prohibited under M1.1 or M1.3 ... For the plasma recipient, plasmapheresis would only be prohibited under M2.2 if it is not legitimately received in the course ...
Page 1 | Search Results | Acta Haematologica | Karger Publishers
These symptoms have been controlled by the use of a regular plasmapheresis regime and associated with a reduction in IgG level ... Open the PDF for Successful ,span class=search-highlight,Plasmapheresis,/span, in Corticosteroid-Resistant Hemolysis in ... Four out of 5 patients responded to plasmapheresis and only 1 patient required cytotoxic therapy. TTP in association with SLE ... Successful Plasmapheresis in Corticosteroid-Resistant Hemolysis in Infectious Mononucleosis: Role of Autoantibodies against ...
PLASMAPHERESIS IN THE TREATMENT OF MYASTHENIA GRAVIS: OUTCOME AND COMPLICATIONS
| Pakistan Armed Forces Medical Journal
...
Repeated plasmapheresis treatmentBenefits of plasmapheresisAntibodiesTherapeuticManaging-RelapsesAutoimmuneIVIGNexSys PCSIntravenous immunoglobulinThrombotic thromboHemodialysisImmune complexesTherapyTreatmentProcedureCyclophosphamideMyastheniaPatientsSteroidsSystemicTreatmentsSymptomsMedicalSyndromeSecondarySignificantlyCasePlasma exchangeClinicalRemoveSearchResultsBlood cellsImprovementHelps
Repeated plasmapheresis treatment1
- The buildup of disease contributing plasma components will continue after plasmapheresis if the underlying disease or disorder is not identified and treated, resulting in repeated plasmapheresis treatment being required. (wagwalking.com)
Benefits of plasmapheresis3
- What are the benefits of plasmapheresis? (health-wiser.com)
- The Lupus Plasmapheresis Study Group (LPSG) aims to study the potential benefits of plasmapheresis and pulse cyclophosphamide in improving treatment results in SLE. (itsreleased.com)
- In order to learn more about the possible benefits of plasmapheresis and pulse cyclophosphamide, a group of clinics have joined forces to form the LPSG. (itsreleased.com)
Antibodies5
- After plasma separation, the blood cells are returned to the person undergoing treatment, while the plasma, which contains the antibodies, is first treated and then returned to the patient in traditional plasmapheresis. (wikipedia.org)
- In published case series and one randomized trial, plasmapheresis has been shown to be beneficial in the treatment of Goodpasture syndrome by removal of anti-GBM antibodies. (medscape.com)
- [ 24 , 25 ] Plasmapheresis is generally instituted after the diagnosis of Goodpasture syndrome is established either by renal biopsy or by detection of anti-GBM antibodies. (medscape.com)
- The plasmapheresis is continued for 2-3 weeks or until the patient's clinical course has improved and serum anti-GBM antibodies are not detected. (medscape.com)
- According to the "antibody rebound" theory, lymphocytes may become more active after plasmapheresis removes circulating antibodies. (itsreleased.com)
Therapeutic3
- Walters G. Role of therapeutic plasmapheresis in ANCA-associated vasculitis. (epnet.com)
- Plasmapheresis is a therapeutic option in patients with recalcitrant disease. (pharmascholars.com)
- Plasmapheresis is also employed for therapeutic use. (bvsalud.org)
Managing-Relapses1
- Available at: https://www.nationalmssociety.org/Treating-MS/Managing-Relapses/Plasmapheresis. (epnet.com)
Autoimmune5
- An important use of plasmapheresis is in the therapy of autoimmune disorders, where the rapid removal of disease-causing autoantibodies from the circulation is required in addition to other medical therapy. (wikipedia.org)
- Plasmapheresis is effective for rapid reduction of toxins or immune complexes in plasma in your dog, thus making it a useful therapy for autoimmune disorders. (wagwalking.com)
- However, when plasmapheresis is used to treat autoimmune diseases, the patient's entire plasma volume is replaced with that of a donor. (grimtrojan.com)
- Also, plasmapheresis was felt to be an invaluable tool for investigating the autoimmune theory of schizophrenia. (johnshopkins.edu)
- Whereas plasmapheresis has been round for a number of many years and has lengthy been utilized in treating autoimmune illnesses, Peak Human is the primary and solely medical heart in Canada that gives to carry out plasmapheresis for mind well being and longevity functions, due to Dr. Goel's in depth analysis and capabilities within the biohacking and longevity discipline. (healthyjournaling.com)
IVIG1
- Oral steroids, cyclophosphamide, plasmapheresis and IVIG therapy were only partially successful, so we. (karger.com)
NexSys PCS1
- Inspired by extensive customer input, the NexSys PCS® plasmapheresis system is designed to improve the key performance indicators that matter to you: Productivity, Quality & Compliance, Yield, and Donor Satisfaction. (medicalexpo.com)
Intravenous immunoglobulin2
- Plasmapheresis or intravenous immunoglobulin. (hopkinsmedicine.org)
- Guillain-Barré syndrome is an immune-mediated polyneuropathy that is routinely initially treated with either intravenous immunoglobulin or plasmapheresis. (biomedcentral.com)
Thrombotic thrombo2
- Plasmapheresis of the autologous and exchange types is used to treat a variety of disorders, including those of the immune system, such as Goodpasture's syndrome, Guillain-Barré syndrome, lupus, myasthenia gravis, and thrombotic thrombocytopenic purpura. (wikipedia.org)
- Two patients with thrombotic thrombocytopenic purpura (TTP) have recovered completely after intensive plasmapheresis. (ashpublications.org)
Hemodialysis2
- Transfer to a hospital where plasmapheresis and/or hemodialysis is available may be necessary. (medscape.com)
- Abstract: Interest in the effects and possible mechanisms of hemodialysis on schizophrenic patients has led to a double‐blind evaluation of the effects of plasmapheresis on symptoms of schizophrenia. (johnshopkins.edu)
Immune complexes1
- It is believed that plasmapheresis, which involves drawing plasma out of blood, is vital in removing harmful immune complexes and autoantibodies. (itsreleased.com)
Therapy8
- Three general types of plasmapheresis can be distinguished: Autologuous, removing blood plasma, treating it in some way, and returning it to the same person, as a therapy. (wikipedia.org)
- citation needed] Plasmapheresis is used as a therapy in particular diseases. (wikipedia.org)
- However, if results are urgent or other therapy fails, plasmapheresis can be a useful option for treatment in your dog. (wagwalking.com)
- During and immediately after plasmapheresis therapy, your dog may experience a drop in blood pressure resulting in dizziness, chills and abdominal cramps. (wagwalking.com)
- We describe a case of amiodarone-induced thyrotoxicosis and thyroid storm leading to refractory ventricular tachycardias treated with plasmapheresis when anti-arrhythmic therapy became contraindicated. (journalmc.org)
- Plasmapheresis appears to be useful therapy for some patients with this syndrome. (ashpublications.org)
- Four out of 5 patients responded to plasmapheresis and only 1 patient required cytotoxic therapy. (karger.com)
- cyclosporine , plasmapheresis or IV immune globulin, early corticosteroid therapy, and tumor necrosis factor-alpha inhibitors have been used. (msdmanuals.com)
Treatment16
- Plasmapheresis (from the Greek πλάσμα, plasma, something molded, and ἀφαίρεσις aphairesis, taking away) is the removal, treatment, and return or exchange of blood plasma or components thereof from and to the blood circulation. (wikipedia.org)
- RBC aggregation and plasma viscosity were significantly lower (p less than 0.001) after the last plasmapheresis than before treatment. (qxmd.com)
- You have been diagnosed with a condition that requires plasmapheresis treatment. (health-wiser.com)
- Plasmapheresis treatment can be incredibly beneficial for people suffering from various health conditions, including lupus, rheumatoid arthritis, and multiple sclerosis. (health-wiser.com)
- If you decide to proceed with treatment, a nurse or technician will bring you to the treatment room, where you will be hooked up to the plasmapheresis machine. (health-wiser.com)
- However, other immunosuppressive and anti-toxicity treatments that are available take time to be effective, whereas plasmapheresis is a fast acting treatment and may be appropriate in some acute situations. (wagwalking.com)
- Plasmapheresis treatment ranges from $500 to $3,000 or more depending on the cost of living in your area and the number of treatments required. (wagwalking.com)
- The LPSG trial will compare pulse cyclophosphamide versus repeated plasmapheresis followed by cyclophosphamide, with a third part collecting data from a more thorough process to understand the advantages and disadvantages of various treatment methods. (itsreleased.com)
- Treatment may take advantage of increased lymphocyte activity following plasmapheresis by timing pulse cyclophosphamide, which may lead to more targeted immune responses. (itsreleased.com)
- Under the circumstances of limited medical therapies, plasmapheresis can be an effective treatment option. (journalmc.org)
- Five patients received plasmapheresis as initial treatment while 1 patient received plasma infusions only. (karger.com)
- This has led patients to seek expensive treatment through plasmapheresis, a procedure that takes blood out of the body and filters it. (evidence4health.org)
- There is currently no evidence indicating that amyloid fibrin(ogen) particles contribute to post-COVID-19 condition, and no justification for people to seek treatment with plasmapheresis to remove amyloid fibrin(ogen) particles. (evidence4health.org)
- To the best of our knowledge, no association between plasmapheresis treatment and acute onset of facial neuropathy has been reported. (biomedcentral.com)
- To the best of our knowledge, no prior cases of acute facial palsy developing during plasmapheresis treatment are known. (biomedcentral.com)
- and treatment, including plasmapheresis and immunosuppression, he experienced a relentless downhill course. (medscape.com)
Procedure1
- Plasmapheresis is a procedure to exchange plasma in the blood. (epnet.com)
Cyclophosphamide6
- To find out how well plasmapheresis and pulse cyclophosphamide work together to treat severe SLE, the Lupus Plasmapheresis Study Group (LPSG) has set out on an innovative mission. (itsreleased.com)
- The study will compare pulse cyclophosphamide alone and repeated plasmapheresis before cyclophosphamide pulses. (itsreleased.com)
- Pulsed cyclophosphamide alone and repeated plasmapheresis before cyclophosphamide pulses are the two groups that will be compared in this randomised investigation. (itsreleased.com)
- Pulsed cyclophosphamide given soon after plasmapheresis may take advantage of this enhanced activity to enhance clonal elimination. (itsreleased.com)
- Pulsed cyclophosphamide versus repeated plasmapheresis followed by cyclophosphamide is the comparison under investigation in the LPSG trial, a randomised controlled trial. (itsreleased.com)
- Plasmapheresis plus pulse cyclophosphamide is expected to improve clearance of harmful autoantibodies and immunological complexes, which is the main benefit. (itsreleased.com)
Myasthenia1
- Assessment of respiratory function using combined oximetry-cutaneous capnography has never been evaluated in patients with myasthenia gravis (MG). We investigated the effects of double filtration plasmapheresis (DFPP) on respiratory status in 18 MG patients. (tmu.edu.tw)
Patients5
- Microcirculatory and haemorheological parameters were investigated before and after plasmapheresis in eighteen patients with secondary Raynaud's phenomenon based on progressive systemic sclerosis. (qxmd.com)
- After 4 plasmaphereses, once a week, all patients claimed explicit improvement of their complaints. (qxmd.com)
- In these patients, plasmapheresis can be considered to treat severe ischemia of the digits. (qxmd.com)
- However, significantly fewer patients in the plasmapheresis group experienced reduced IgG (62.7% vs. 83.5%), and the plasmapheresis group also experienced fewer plasma-associated side effects. (medscape.com)
- Patients (n = 10) in the study fulfilled Research Diagnostic Criteria for schizophrenia and were randomly assigned to either sham or active plasmapheresis. (johnshopkins.edu)
Steroids1
- Severe Cholestasis and Bile Acid Nephropathy From Anabolic Steroids Successfully Treated With Plasmapheresis. (bvsalud.org)
Systemic1
- Plasmapheresis in Raynaud's phenomenon in systemic sclerosis: a microcirculatory study. (qxmd.com)
Treatments2
- Plasmapheresis is usually used after initial, less invasive treatments fail. (wagwalking.com)
- Multiple plasmapheresis procedures may be required, which will contribute to variations in cost depending on the number of treatments required. (wagwalking.com)
Symptoms1
- These symptoms have been controlled by the use of a regular plasmapheresis regime and associated with a reduction in IgG level. (karger.com)
Medical1
- As a medical process, Houston plasmapheresis separates plasma from whole blood. (health-wiser.com)
Syndrome4
- Hyperviscosity syndrome M-component Plasma cell leukemia Plasmapheresis Acta haemat. (karger.com)
- The possible mechanism of plasmapheresis-induced worsening of peripheral nerve function in Guillain-Barré syndrome is unknown. (biomedcentral.com)
- The patient was initially treated for an acute peripheral demyelinating process, such as Guillain-Barre Syndrome (GBS), with corticosteroids and plasmapheresis. (cdc.gov)
- SARS-CoV-2-Associated Guillain-Barre Syndrome With Good Response to Plasmapheresis. (cdc.gov)
Secondary1
- When a patient presents in a life-threatening situation secondary to pulmonary hemorrhage, however, plasmapheresis may be initiated if the diagnosis appears very likely, even though confirmation is not available immediately. (medscape.com)
Significantly1
- Red blood cell (RBC) velocity increased significantly (p less than 0.001) after 4 weeks plasmapheresis. (qxmd.com)
Case1
- In this case, plasmapheresis (PP) allows a recipient to accept just plasma the yellow liquid in which the blood cells are suspended. (grimtrojan.com)
Plasma exchange1
- Plasma exchange (plasmapheresis). (medicinenet.com)
Clinical1
- Plasmapheresis should be considered in special cases in which there is progressive clinical decline despite supportive care. (bvsalud.org)
Remove2
- Dogs with these conditions can undergo plasmapheresis to remove and replace components of their plasma contributing to disease with "healthy" plasma components. (wagwalking.com)
- Fox T, Hunt BJ, Ariens RAS, Towers GJ, Lever R, Garner P, Kuehn R. Plasmapheresis to remove amyloid fibrin(ogen) particles for treating the post‐COVID‐19 condition . (evidence4health.org)
Search1
- The review authors conducted a search of the literature on 21 October 2022 to determine if there is any evidence from randomized controlled trials (RCTs) that plasmapheresis is safe and effective for removing these amyloid fibrin(ogen) particles but found no completed studies. (evidence4health.org)
Results1
- Scientists have proven that Plasmapheresis seems to have promising regenerative results in animals and people. (healthyjournaling.com)
Blood cells1
- During plasmapheresis, blood, which consists of blood cells and a clear liquid called blood plasma, is initially taken out of the body through a needle or previously implanted catheter. (wikipedia.org)
Improvement1
- We highlight the use of plasmapheresis resulting in rapid improvement in cholestatic jaundice with resolution of AKI. (bvsalud.org)
Helps1
- Plasmapheresis helps revert the affected person's plasma profile to that of a youthful particular person thereby offering rejuvenating advantages. (healthyjournaling.com)
